GRAMMY Museum® Grant Program Awards $200,000 for Music Research and Sound Preservation
Article content
Article content
LOS ANGELES — The GRAMMY Museum ® Grant Program announced today that $200,000 in grants will be awarded to 15 recipients in the United States to help facilitate a range of research on a variety of subjects, as well as support a number of archiving and preservation programs.
Article content
'The GRAMMY Museum and Recording Academy ® have continued their partnership to provide fundamental funding for music research and preservation projects across the United States and Canada. We are incredibly inspired by this year's recipients and what they set to accomplish,' said Michael Sticka, President/CEO of the GRAMMY Museum. 'Our mission is to lead in fostering a world where a shared passion for music fuels curiosity, creativity and community. We are honored to support these remarkable projects that continue to shape the future of music, science and technology.'
Article content
Article content
Generously funded by the Recording Academy, the GRAMMY Museum Grant Program provides funding annually to organizations and individuals to support efforts that advance the archiving and preservation of the recorded sound heritage of the Americas for future generations, in addition to research projects related to the impact of music on the human condition. In 2008, the GRAMMY Museum Grant Program expanded its categories to include assistance grants for individuals and small to mid-sized organizations to aid collections held by individuals and organizations that may not have access to the expertise needed to create a preservation plan. The assistance planning process, which may include inventorying and stabilizing a collection, articulates the steps to be taken to ultimately archive recorded sound materials for future generations. This year marks the 37th year of the program.
Article content
More information about the program can be found at www.grammymuseum.org.
Article content
CERVO Brain Research Center — Quebec City, QC
Awarded: $20,000
Their goal is to uncover how choir singing impacts communication (voice, articulation, listening) and auditory cognition in older adults, supporting healthy aging through a randomized training study. We further explore neurobiological mechanisms underlying these changes via multimodal brain imaging. This project aims to inform community choirs and music-based interventions, aligning with the foundation's mission to enhance quality of life through music.
Article content
Jewish Rehabilitation Hospital – CISSS Laval — Laval, QC
Awarded: $19,500
Stroke typically leads to persistent deficits in arm and hand function. This project will examine the feasibility, acceptability and preliminary effectiveness of a 6-week piano training intervention aimed at improving manual dexterity and the functional use of the arm and hand. For the first time, such intervention will be delivered as part of a home-based, early, and intensive rehabilitation program for individuals with stroke.
Article content
New York University — New York, NY
Awarded: $9,000
Many people struggle with speech-language disorders due to developmental issues or brain injuries. Although music therapy can help these individuals regain speech functions, its effectiveness varies because we don't fully understand the underlying brain mechanisms. By combining neuroimaging and machine learning, this study will explore how the brain can 'bypass' damaged speech-language networks by leveraging musical networks to enhance communication.
Article content
Article content
University of South Florida — Tampa, FL
Awarded: $9,000
This randomized trial will examine the effects of a novel woodwind program on neural responses and respiration function in adults 50+ with Long-term COVID (LTC). Adults will complete measures of cognitive processing (EEG) and respiration function (spirometer), pre and post-10 weeks of either Nuvo jsax lessons or an attentional control task. We predict that a woodwind program will enhance cognitive processing and respiration function in adults with LTC.
Article content
University of Toronto — Toronto, ON
Awarded: $20,000
Rhythmic Auditory Stimulation (RAS ®) uses rhythmic sound cues to help people with Parkinson's disease (PD) start and maintain stable movement. This project is the first to examine how these cues impact brain chemistry in PD, revealing the brain's response to these cues. Their findings could improve the use of RAS as part of PD care, refining clinical applications that work alongside standard medication to support movement and enhance quality of life in PD.
Article content
Lex Gillespie — Washington, D.C.
Awarded: $5,000
The project will preserve 75 interviews from the 10-hour Peabody Award-winning public radio series, 'Whole Lotta Shakin'.' It tells the story of rockabilly, the exciting 1950s mix of blues, gospel and country that is the cornerstone of rock and roll. This diverse collection features singers, musicians, producers, disc jockeys, and record company owners. The goal: to digitize these decaying recordings for use by scholars, content providers and the public.
Article content
Memphis Listening Lab — Memphis, TN
Awarded: $5,000
GRAMMY Museum Preservation Assistance funding will enable the Memphis Listening Lab (MLL) to hire an expert consultant to conduct a Preservation Assessment of MLL's extensive collection of recorded music. The consultant will be drawn from the GRAMMY Museum's list of recommended experts and will provide MLL with a written report detailing their observations and recommendations for preserving MLL's collection, which is freely accessible to the public.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 days ago
- Cision Canada
Specific Biologics Welcomes Paul J. Hastings as Chair of the Board of Directors
TORONTO, June 11, 2025 /CNW/ - Specific Biologics Inc., a biotechnology company advancing Dualase® genome editors for precise and programmable in vivo genome editing, today announced the appointment of Paul J. Hastings as Chair of its Board of Directors. Mr. Hastings is a distinguished leader in the biopharmaceutical industry and currently serves as Chief Executive Officer and Board Member of engineered cell therapy company Nkarta since 2018. He is also a current Director of EnGene, a non-viral gene therapy company, and recently served as the Chair of the Biotechnology Innovation Organization (BIO). Over his career, he has held numerous top leadership roles, including CEO of OncoMed, QLT, Axys Pharmaceuticals, and LXR Biotechnology, and President of Chiron BioPharmaceuticals. He has guided corporate strategy as Chair of Pacira Biosciences, Proteon Therapeutics and Proteolix, and as a Director of ViaCyte, Relypsa and ViaCell, and previously held leadership roles in global biotechnology companies as President of Genzyme Therapeutics Europe and Genzyme Global Therapeutics, as well as progressive executive roles at Hoffmann-La Roche. A committed mentor and patient advocate, he co-founded and chairs the board of Youth Rally Inc. and serves on the Board of the Termeer Foundation. "I am thrilled to welcome Paul to the Board," said Brent Stead, CEO of Specific Biologics. "His proven ability to lead and scale high-impact biotechnology companies with breakthrough technologies will be instrumental as we advance our Dualase® platform toward the clinic for patients in need. We are entering an exciting new phase of growth, and Paul's leadership of the Board will be invaluable." "I'm honored to join the Board of Specific Biologics at such a pivotal time," said Hastings. "The Dualase® technology has the potential to reshape how we approach treating some of the most challenging genetic diseases. I look forward to working with the leadership team and Board to support Specific's mission and drive meaningful impact for patients with limited therapeutic options." Specific Biologics also extends its sincere gratitude to Dr. Steven Kanner for his dedicated service on the Board and guidance during a critical phase of the company's development. "Steve played a key role in helping shape our early strategy and set the foundation for our current momentum," said Stead. About Specific Biologics Inc. Specific Biologics is a venture-backed biotechnology company developing Dualase®, an industry-leading genome editing platform for precise, efficient, and programmable in vivo genome editing, with an initial therapeutic focus on the precise collapse of pathogenic repeat expansions in neurodegenerative disease. Its unique two-site mechanism enables the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all-RNA delivery. Dualase® achieves best-in-class accurate editing efficiency with undetectable off-target effects as demonstrated in preclinical cell and animal models at diverse targets and indications.
Cision Canada
05-06-2025
- Cision Canada
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /CNW/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.
Cision Canada
04-06-2025
- Cision Canada
Fresenius Kabi Canada launches Iodixanol Injection 270 & 320 - the first and only generic to Visipaque® in Canada Français
Fresenius Kabi received Health Canada's Notice of Compliance (NOC) approval for Iodixanol injection on December 17 for both intravenous and intra-arterial administration With the launch of Iodixanol injection, Fresenius Kabi Canada is looking to expand into the contrast media space, with a commitment to bring more treatment options for patients requiring diagnostic imaging Iodixanol injection is approved for all indications of the reference product Visipaque ® and available immediately TORONTO, June 4, 2025 /CNW/ - Fresenius Kabi Canada, part of Fresenius group, announced the recent launch of Iodixanol Injection 270 and 320 for both the intravenous and intra-arterial administrations. Iodixanol Injection is a contrast agent with uses in angiocardiography, arteriography, CT scanning of head and body, excretory urography and venography. Health Canada's NOC approval of Iodixanol Injection 270 & 320 was granted on December 17, 2024, and is based on a thorough evaluation of a comprehensive data package demonstrating pharmaceutical equivalence to the reference drug Visipaque ®. With this approval, Fresenius Kabi is building its footprint in the contrast media space in Canada, following recent successful launches of contrast media products in the United States. Expanding a strong presence into the imaging agent space is a substantial cornerstone of Fresenius Kabi's Vision 2026 and the #FutureFresenius strategy. "Fresenius Kabi's Iodixanol Injection will be the first generic for injectable iodinated contrast media on the market in Canada," said Lee Fulford Sr. Marketing Manager, Specialty Pharma at Fresenius Kabi Canada. "With this launch we are committed to bringing value to Canadians, by lowering the cost as well as adding supply stability to a market that has had devastating shortages historically." In recent years global shortages of iodinated contrast media have led to Canadian healthcare agencies having to adopt strategies to mitigate shortages including selecting which patients would get contrast and reducing dosages where possible 1. Iodixanol injection was added in June 2022 to Health Canada's tier 3 drug shortage list. Tier 3 drug shortages are those likely to have the greatest potential impact to the Health Care system 2. "We are proud to be introducing an affordable alternative Iodixanol diagnostic option which will strengthen Canada's supply for this critical agent. This launch underscores our commitment to enhancing patient care through accessible therapies," said Martin Willner, General Manager, Fresenius Kabi Canada. About Fresenius Kabi: Fresenius Kabi, an operating company of Fresenius, specializes in clinical nutrition, medical technologies, and I.V. generics and fluids for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. About Iodixanol Injection Iodixanol injection is a non-ionic radiographic contrast medium with uses in angiocardiography, arteriography, CT scanning of head and body, excretory urography and venography. The lower osmolality of Iodixanol Injection (which is isotonic with blood) compared with conventional contrast media of similar iodine concentration can be expected to cause fewer and less severe osmolality-related disturbances, specifically, less pain, heat and burning sensation, upon injection 3. Fresenius Kabi's Iodixanol Injection is free of preservatives and comes in a polymer bottle. The container closure is not made with natural rubber latex. Fresenius Kabi Iodixanol Injection is currently available in six presentations for intra-arterial and intravenous procedures: 270 mg Iodine per mL: 100 mL polymer bottle 150 mL polymer bottle 320 mg Iodine per mL: 50 mL polymer bottle 100 mL polymer bottle 150 mL polymer bottle 200 mL polymer bottle For more information, please visit This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release. Management Board: Pierluigi Antonelli (Chairman), Marc Crouton, Andreas Duenkel, Dr. Christian Hauer, Dr. Marc-Alexander Mahl, Dr. Sang-Jin Pak Chairman of the Supervisory Board: Wolfgang Kirsch Registered Office: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg - HRB 11654
